Neuronetics(STIM) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue in Q4 2025 was $41.8 million, an increase of 86% compared to $22.5 million in Q4 2024, primarily driven by the inclusion of Greenbrook operations following the acquisition [17] - Adjusted pro forma revenue growth for Q4 was 23% year-over-year [17] - Net loss for Q4 2025 was $7.2 million, or $0.10 per share, compared to a net loss of $12.7 million, or $0.34 per share in the prior year [20] - EBITDA for Q4 2025 was negative $4.3 million, an improvement from negative $11 million in the prior year [20] - Cash provided by operations in Q4 was positive $0.9 million, marking a significant improvement from negative cash flow earlier in the year [21] Business Line Data and Key Metrics Changes - NeuroStar business revenue, including system and treatment session revenue, was $18.3 million in Q4 2025, representing a 9% increase on a pro forma basis [17] - U.S. NeuroStar system revenue was $4.4 million, a 15% year-over-year increase, with 49 systems shipped in the quarter [18] - U.S. treatment session revenue was $12.4 million, with a pro forma increase of 6% compared to the prior year [18] - Clinic revenue for Q4 was $23.5 million, a 37% increase on an adjusted pro forma basis, driven by growth in treatments across both NeuroStar TMS and Spravato [18] Market Data and Key Metrics Changes - The referring provider network added 430 new providers in Q4, a 25% increase year-over-year, contributing to over 1,300 new referrers added across 2025 [7] - Total treatment volume increased by 18% year-over-year in Q4 [9] - The expansion of TRICARE West coverage for TMS therapy to include adolescents aged 15 and older is a significant development for military families [13] Company Strategy and Development Direction - The company aims to leverage its integrated model to drive growth through expanding how NeuroStar TMS systems are brought to market and addressing the unmet need for treatment-resistant depression (TRD) [26][28] - Collaboration with Compass Pathways on COMP360 psilocybin is seen as a potential transformational treatment for TRD, with plans for commercial launch upon FDA approval [28][29] - The company is focused on operational efficiency and expects to reduce operating expenses to less than $100 million by Q4 2026 [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive revenue growth and achieve sustainable operating cash flow, with expectations for positive cash flow in the second half of 2026 [25] - The company acknowledges seasonality impacts on revenue, particularly in Q1, and is adapting its strategies accordingly [55][56] - Management highlighted the importance of maintaining strong relationships with primary care physicians and enhancing patient access to treatments [26] Other Important Information - The company appointed Dan Reuvers as the new President and CEO, effective March 23, 2026, indicating a leadership transition [5] - The company has made significant progress in integrating Greenbrook's operations, achieving positive operating cash flow and strengthening its balance sheet [16] Q&A Session Summary Question: Can you provide details on the CID investigation in Florida and Michigan? - Management confirmed that they are cooperating with the U.S. Attorney's Office regarding documentation for billing practices prior to the Greenbrook acquisition [36] Question: What are the profitability and patient monitoring differences for COMP360? - The treatment effect of COMP360 appears durable after one or two doses, and it will be administered under a REMS protocol similar to Spravato [40][42] Question: How did the $5 million payment to Perceptive affect cash position? - The payment did not come from restricted cash, and the company remains comfortable with its cash position despite projected Q1 cash burn [43][44] Question: Can you elaborate on the growth guidance for the clinic and standalone businesses? - Majority of growth in the clinic business is expected to come from volume, with Spravato growth anticipated to be significant in Q1 due to buy-and-bill impacts [50] Question: What are the integration requirements for the Compass collaboration? - The existing infrastructure for Spravato clinics will facilitate the integration of COMP360 treatments, with minimal additional updates needed [68]